These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23184711)

  • 1. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.
    Reigadas S; Marcelin AG; Houssaïni A; Yerly S; Descamps D; Plantier JC; Ruffault A; Amiel C; Trabaud MA; Flandre P; Fleury H; Masquelier B;
    J Antimicrob Chemother; 2013 Apr; 68(4):969-72. PubMed ID: 23184711
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir.
    Young TP; Napolitano LA; Paquet AC; Parkin NT; Fransen S; Trinh R; Haddad M; Hackett J; Cloherty GA
    J Virol Methods; 2013 Nov; 193(2):693-6. PubMed ID: 23892128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
    Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C
    J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appearance of Drug Resistance-Associated Mutations in Human Immunodeficiency Virus Type 1 CRF01_AE Integrase Derived from Drug-Naive Thai Patients.
    Isarangkura-Na-Ayuthaya P; Kaewnoo W; Auwanit W; de Silva UC; Ikuta K; Sawanpanyalert P; Kameoka M
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1341-3. PubMed ID: 20836708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
    Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
    Ceccherini-Silberstein F; Malet I; Fabeni L; Dimonte S; Svicher V; D'Arrigo R; Artese A; Costa G; Bono S; Alcaro S; Monforte Ad; Katlama C; Calvez V; Antinori A; Marcelin AG; Perno CF
    J Antimicrob Chemother; 2010 Nov; 65(11):2305-18. PubMed ID: 20817922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to etravirine of HIV type 1 subtype C isolates from nevirapine/efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
    Anquetil D; Deshpande A; Zongo D; Le Bihan L; Pinson PR; Fleury HJ
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1793-7. PubMed ID: 22519709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 12. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
    Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
    J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
    Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
    Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA
    AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
    Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
    Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
    J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naïve individuals in a tertiary care hospital in Beijing, China.
    Liu L; Dai L; Yao J; Pan P; Li L; Liu Z; An X; Sun L; Wu H; Su B; Zhang T
    AIDS; 2019 Oct; 33(12):1945-1947. PubMed ID: 31491787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of drug resistance-associated mutations in human immunodeficiency virus type 1 integrase derived from drug-naive individuals in Surabaya, Indonesia.
    Kotaki T; Khairunisa SQ; Sukartiningrum SD; Witaningrum AM; Rusli M; Diansyah MN; Arfijanto MV; Rahayu RP; Nasronudin ; Kameoka M
    AIDS Res Hum Retroviruses; 2014 May; 30(5):489-92. PubMed ID: 24328535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir: successful experience in a challenging patient.
    Bonadies G; Maraolo AE; Tambaro O; Palmiero G; Di Filippo G; Orlando R
    AIDS; 2015 Jun; 29(10):1269-71. PubMed ID: 26035327
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.